InvestorsHub Logo

rosemountbomber

10/23/19 6:02 AM

#220596 RE: Jt0082 #220595

Thanks for posting Jt. Not thrilled with the poll results.

couldbebetter

10/23/19 6:55 AM

#220598 RE: Jt0082 #220595

Interesting article. I like the answer to the question in the last
paragraph. The survey question and the answers voted on provide insight
into what AMRN is up against...regardless of what evidence is presented
about the effectiveness of Vascepa, there will always be those who will
doubt it.

flubber

10/23/19 8:07 AM

#220602 RE: Jt0082 #220595

@ Jt0082...Thanks for the PACE link and the poll

For those that did not scroll all the way thru the article, there was a link to Dr. Bhatt video statement at 2018 AHA meeting regarding Reduce-It and VITAL trials.

Here is the link for iHub readers that may not have seen it before. Concise and to the point.

https://pace-cme.org/2018/11/13/not-all-fish-oils-are-created-equal-different-compounds-have-different-effects/


Cheers!
Flubber

tke458

10/23/19 9:52 AM

#220624 RE: Jt0082 #220595

This article is extremely positive IMO and reminds me of the scene in Cinderella Man when Paul Giamatti is trying to convince Bruce Mcgill that Braddock (Crowe) should be able to fight. In either scenario, “you make money....” and while the patient benefits far outweigh the benefits of all of us making money, this article summarized the MOA issue for me. In other words, whether it’s because of TG lowering, lowering of systemic inflammation, other, or some combo of all..... It works. Hard stop.

And while that will potentially affect how the label will read, the label will be expanded IMO and is why all of my shares will be held.